The Supreme Court of India has exempted Saridon from the list of banned fixed-dose combinations (FDCs) in the country.
FDCs contain more than two active ingredients in a fixed proportion.
Saridon, which is a combination of propyphenazone, paracetamol and caffeine, is a popular analgesic brand promoted by Piramal Enterprises Limited (PEL), Mumbai
PEL had challenged the ban of Saridon in the SC listing it under the irrational combination of drugs. In September 2018, SC allowed the company to continue manufacturing, distribution and sale of the FDC through an interim order staying the ban.
Now with the lifting of the ban, Saridon will be available across the country.
Last year, India’s health ministry slapped a ban on over 300 FDCs as an expert committee set up of for the purpose concluded that there was no therapeutic justification for such combinations.
Saridon is one of the leading brands in India›s analgesics market, which is estimated to be worth around Rs 2,050 crores as of December 2018.